1. Hughes IA. Congenital adrenal hyperplasia: a continuum of disorders. Lancet 1998;352:752–4.
2. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003;349:776–88.
4. Riepe FG, Sippell WG. Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Rev Endocr Metab Disord 2007;8:349–63.
5. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245–91.
6. Sharma R, Seth A. Congenital adrenal hyperplasia: issues in diagnosis and treatment in children. Indian J Pediatr 2014;81:178–85.
8. Gruneiro-Papendieck L, Prieto L, Chiesa A, Bengolea S, Bossi G, Bergada C. Neonatal screening program for congenital adrenal hyperplasia: adjustments to the recall protocol. Horm Res 2001;55:271–7.
9. Honour JW, Torresani T. Evaluation of neonatal screening for congenital adrenal hyperplasia. Horm Res 2001;55:206–11.
10. Ballerini MG, Chiesa A, Scaglia P, Gruneiro-Papendieck L, Heinrich JJ, Ropelato MG. 17Alpha-hydroxyprogesterone and cortisol serum levels in neonates and young children: influence of age, gestational age, gender and methodological procedures. J Pediatr Endocrinol Metab 2010;23:121–32.
11. Masumoto K, Kusuda S, Aoyagi H, Tamura Y, Obonai T, Yamasaki C, et al. Comparison of serum cortisol concentrations in preterm infants with or without late-onset circulatory collapse due to adrenal insufficiency of prematurity. Pediatr Res 2008;63:686–90.
12. Steigert M, Schoenle EJ, Biason-Lauber A, Torresani T. High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. J Clin Endocrinol Metab 2002;87:4106–10.
13. Cavarzere P, Camilot M, Teofoli F, Tato L. Neonatal screening for congenital adrenal hyperplasia in North-Eastern Italy: a report three years into the program. Horm Res 2005;63:180–6.
14. van der Kamp HJ, Oudshoorn CG, Elvers BH, van Baarle M, Otten BJ, Wit JM, et al. Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab 2005;90:3904–7.
15. Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 1997;130:128–33.
17. Kunze M, Hart JE, Lynch AM, Gibbs RS. Intrapartum management of premature rupture of membranes: effect on cesarean delivery rate. Obstet Gynecol 2011;118:1247–54.
20. Chung HR, Shin CH, Yang SW, Yun KA, Lee YA, Park SE, et al. Interpretation of screening for congenital adrenal hyperplasia in preterm infants. Korean J Pediatr 2008;51:616–21.
22. R Core Team. R: a language and environment for the statistical computing [Internet]. Vienna:R Foundation for Statistical Computing, 2019;[cited 2019 Jan 4]. Available from:
https://cran.r-project.org/mirrors.html.
23. Cavarzere P, Samara-Boustani D, Flechtner I, Dechaux M, Elie C, Tardy V, et al. Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol 2009;161:285–92.
24. Choi YS, Lee BS, Kim KS, Kim EA. Study of 17-alpha-hydroxy progesterone in preterm infants. J Korean Soc Neonatol 2012;19:77–83.
26. Chennuri VS, Mithbawkar SM, Mokal RA, Desai MP. Serum 17 alpha hydroxyprogesterone in normal full term and preterm vs sick preterm and full term newborns in a tertiary hospital. Indian J Pediatr 2013;80:21–5.
28. King JL, Naber JM, Hopkin RJ, Repaske DR, Bailey L, Leslie ND. Antenatal corticosteroids and newborn screening for congenital adrenal hyperplasia. Arch Pediatr Adolesc Med 2001;155:1038–42.
29. Gatelais F, Berthelot J, Beringue F, Descamps P, Bonneau D, Limal JM, et al. Effect of single and multiple courses of prenatal corticosteroids on 17-hydroxyprogesterone levels: implication for neonatal screening of congenital adrenal hyperplasia. Pediatr Res 2004;56:701–5.
30. Travers S, Martinerie L, Boileau P, Lombes M, Pussard E. Alterations of adrenal steroidomic profiles in preterm infants at birth. Arch Dis Child Fetal Neonatal Ed 2018;103:F143–51.
33. Berry J, Betts P, Wood PJ. The interpretation of bloodspot 17 alpha-hydroxyprogesterone levels in term and pre-term neonates. Ann Clin Biochem 1986;23(Pt 5):546–51.
34. Ohkubo S, Shimozawa K, Matsumoto M, Kitagawa T. Analysis of blood spot 17 alpha-hydroxyprogesterone concentration in premature infants: proposal for cut-off limits in screening for congenital adrenal hyperplasia. Acta Paediatr Jpn 1992;34:126–33.
35. Hingre RV, Gross SJ, Hingre KS, Mayes DM, Richman RA. Adrenal steroidogenesis in very low birth weight preterm infants. J Clin Endocrinol Metab 1994;78:266–70.
36. Huysman MW, Hokken-Koelega AC, De Ridder MA, Sauer PJ. Adrenal function in sick very preterm infants. Pediatr Res 2000;48:629–33.
37. Riepe FG, Mahler P, Sippell WG, Partsch CJ. Longitudinal study of plasma pregnenolone and 17-hydroxypregnenolone in fullterm and preterm neonates at birth and during the early neonatal period. J Clin Endocrinol Metab 2002;87:4301–6.